Foghorn Therapeutics Inc. Common Stock
FHTXFoghorn Therapeutics Inc. (FHTX) is a biotechnology company focused on developing novel cancer therapies by targeting the chromatin regulatory system. Leveraging its proprietary Foghorn Discovery Engine, the company aims to identify and develop innovative treatments for difficult-to-treat cancers and diseases related to gene regulation.
Company News
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep...
Foghorn Therapeutics raised $50 million in equity financing from BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund. The company reported progress on its Phase 1 trial of FHD-909 (partnered with Eli Lilly) for SMARCA4-mutant cancers, with selective CBP and EP300 degrader programs advancing toward IND filings in 202...
4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.
Foghorn Therapeutics, a clinical-stage biotechnology company, announced participation in upcoming healthcare conferences and provided an update on its Phase 1 dose escalation trial for FHD-909 targeting SMARCA4 mutated cancers.
Foghorn Therapeutics reports progress on its oncology drug development pipeline, including the FHD-909 Phase 1 trial for SMARCA4 mutated cancers and advancing selective degrader programs targeting CBP, EP300, and ARID1B, with a strong cash position of $198.7 million through 2028.
Related Companies
